New Review of Critical Decisions
A review of Critical Decisions was recently published in The American Journal of Bioethics. You can check it out here.
(Click here to view comments)
A review of Critical Decisions was recently published in The American Journal of Bioethics. You can check it out here.
(Click here to view comments)
Making important decisions in the dark can be stressful. But a recent study suggests that shining a light on decisions can make decision makers even more anxious. The question remains: Is this anxiety a good thing or a bad …. (Read the rest and view comments at Critical Decisions)
Put simply, shared decision making is the gold standard — the sine qua non* — for how medical decisions ought to be made. The pipe medical choice is rarely a function of medical facts alone. Tough decisions require value judgments, and it is the patient’s valuesthat often determine which choice is best. An operation cannot…
A recent study of men with early-stage prostate cancer found no difference in 10-year death rates, regardless of whether their doctors actively monitored the cancers for signs of growth or eradicated the men’s cancers with surgery or radiation. What does this study mean for patients? Based on research we have conducted on prostate cancer decision-making,…
My colleagues and I have been doing lots of research lately on how physicians and patients discuss out-of-pocket expenses during clinic encounters. One of our recent publications has been getting lots of attention, with this being the latest example. I thought I would share it with you: Recent qualitative findings published in Health Affairs showed that physicians…
Sepsis is a brutal killer. It often starts after a microorganism gets loose in your bloodstream, spreading to organs far and wide, releasing deadly toxins along the way. In response, your body releases toxins of its own, chemicals designed to kill the invading organism but that, all too often, damage your body, too, leaving you…
Chemotherapy drugs have become ridiculously expensive. Many new drugs come to market costing more than $100,000 per patient for a full course of treatment. Often, patients have to pay a significant portion of these costs. For example, a 20% co-insurance rate, typical for basic Medicare coverage, leaves patients responsible for more than $20,000 of chemotherapy costs,…